New York Times
by Gina Kolata

The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a device similar to an insulin pen. The list price will be $6,900 a year, and Amgen said the drug will be available to patients within a week…“The drugs will have a huge impact,” said Dr. Amaal Starling, a neurologist and migraine specialist at the Mayo Clinic in Phoenix. “This is really an amazing time for my patient population and for general neurologists treating patients with migraine.”

Reach: The New York Times has a daily circulation of nearly 589,000. The New York Times online receives more than 29.8 million unique visitors each month.

Additional coverage:
Wall Street Journal, New Migraine Drugs Offer Hope to Sufferers; Men’s Health, Gizmodo, Market Business News, Straits Times, Syracuse.com, Times of India

Context: A migraine is much more than just a bad headache. Migraine symptoms, which can be debilitating for many people, are the sixth leading cause of disability, according to the World Health Organization. “The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,” says Amaal Starling, M.D., a Mayo Clinic neurologist. You can read about some recently published research by Dr. Starling here.

Contact:  Traci Klein

Tags: Dr. Amaal Starling, migraine, New York Times, Uncategorized